REPUBLIC OF BRAZIL
MINISTRY OF HEALTH
OSWALDO CRUZ FOUNDATION

PROFILE
RIO DE JANEIRO 2004
FIOCRUZ MISSION

TO GENERATE, ABSORB AND DIFFUSE SCIENCE & TECHNOLOGY
IN HEALTH THROUGH THE INTEGRATED DEVELOPMENT OF

RESEARCH & TECHNOLOGY
EDUCATION & TRAINING
INFORMATION & COMMUNICATION
PRODUCTION OF GOODS
REFERENCE SERVICES,
QUALITY CONTROL
GEOGRAPHICAL DISTRIBUTION

- CPqMLD
- CPqAM
- DIREB
- CPqGM
- CPqRR
- HQ
- IBMP
## FIOCRUZ STAFF

<table>
<thead>
<tr>
<th>UNIT</th>
<th>Permanent</th>
<th>Contract</th>
<th>Permanent + Contract</th>
<th>Master’s Degree</th>
<th>Doctor’s Degree</th>
<th>% (M+D)</th>
<th>Fellows</th>
<th>Cooperative</th>
<th>Total</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIOMANGUINHOS</td>
<td>193</td>
<td>334</td>
<td>527</td>
<td>25</td>
<td>14</td>
<td>7,40%</td>
<td>1</td>
<td>11</td>
<td>539</td>
<td>6.7%</td>
</tr>
<tr>
<td>CECAL</td>
<td>46</td>
<td>19</td>
<td>65</td>
<td>2</td>
<td>1</td>
<td>4,62%</td>
<td>0</td>
<td>12</td>
<td>77</td>
<td>1.0%</td>
</tr>
<tr>
<td>CICT</td>
<td>93</td>
<td>15</td>
<td>108</td>
<td>8</td>
<td>10</td>
<td>16,67%</td>
<td>9</td>
<td>38</td>
<td>155</td>
<td>1.9%</td>
</tr>
<tr>
<td>COC</td>
<td>105</td>
<td>106</td>
<td>211</td>
<td>31</td>
<td>27</td>
<td>27,49%</td>
<td>31</td>
<td>2</td>
<td>244</td>
<td>3.0%</td>
</tr>
<tr>
<td>CPqAM</td>
<td>115</td>
<td>33</td>
<td>148</td>
<td>19</td>
<td>27</td>
<td>31,08%</td>
<td>0</td>
<td>0</td>
<td>148</td>
<td>1.8%</td>
</tr>
<tr>
<td>CPqGM</td>
<td>72</td>
<td>69</td>
<td>141</td>
<td>5</td>
<td>26</td>
<td>21,99%</td>
<td>10</td>
<td>13</td>
<td>164</td>
<td>2.0%</td>
</tr>
<tr>
<td>CPqL&amp;MD</td>
<td>22</td>
<td>0</td>
<td>22</td>
<td>5</td>
<td>5</td>
<td>45,45%</td>
<td>0</td>
<td>0</td>
<td>22</td>
<td>0.3%</td>
</tr>
<tr>
<td>CPqRR</td>
<td>086</td>
<td>48</td>
<td>134</td>
<td>6</td>
<td>28</td>
<td>25,37%</td>
<td>0</td>
<td>0</td>
<td>134</td>
<td>1.7%</td>
</tr>
<tr>
<td>DIPLAN</td>
<td>25</td>
<td>1</td>
<td>26</td>
<td>5</td>
<td>3</td>
<td>30,77%</td>
<td>1</td>
<td>0</td>
<td>27</td>
<td>0.3%</td>
</tr>
<tr>
<td>DIRAC</td>
<td>220</td>
<td>355</td>
<td>575</td>
<td>15</td>
<td>1</td>
<td>2,78%</td>
<td>17</td>
<td>957</td>
<td>1549</td>
<td>19.4%</td>
</tr>
<tr>
<td>DIRAD</td>
<td>69</td>
<td>59</td>
<td>128</td>
<td>0</td>
<td>0</td>
<td>0,00%</td>
<td>0</td>
<td>11</td>
<td>139</td>
<td>1.7%</td>
</tr>
<tr>
<td>DIREB</td>
<td>11</td>
<td>5</td>
<td>16</td>
<td>2</td>
<td>2</td>
<td>25,00%</td>
<td>1</td>
<td>0</td>
<td>17</td>
<td>0.2%</td>
</tr>
<tr>
<td>DIREH</td>
<td>118</td>
<td>109</td>
<td>227</td>
<td>13</td>
<td>2</td>
<td>6,61%</td>
<td>12</td>
<td>8</td>
<td>247</td>
<td>3.1%</td>
</tr>
<tr>
<td>ENSP</td>
<td>449</td>
<td>166</td>
<td>615</td>
<td>103</td>
<td>112</td>
<td>34,96%</td>
<td>43</td>
<td>14</td>
<td>672</td>
<td>8.4%</td>
</tr>
<tr>
<td>EPSJ</td>
<td>63</td>
<td>3</td>
<td>66</td>
<td>21</td>
<td>4</td>
<td>37,88%</td>
<td>239</td>
<td>45</td>
<td>350</td>
<td>4.4%</td>
</tr>
<tr>
<td>FARMANGUINHOS</td>
<td>65</td>
<td>495</td>
<td>560</td>
<td>12</td>
<td>9</td>
<td>3,75%</td>
<td>7</td>
<td>0</td>
<td>567</td>
<td>7.1%</td>
</tr>
<tr>
<td>IFF</td>
<td>684</td>
<td>26</td>
<td>710</td>
<td>47</td>
<td>22</td>
<td>9,72%</td>
<td>130</td>
<td>316</td>
<td>1156</td>
<td>14.4%</td>
</tr>
<tr>
<td>INCQS</td>
<td>180</td>
<td>105</td>
<td>285</td>
<td>42</td>
<td>15</td>
<td>20,00%</td>
<td>9</td>
<td>15</td>
<td>309</td>
<td>3.9%</td>
</tr>
<tr>
<td>IOC</td>
<td>478</td>
<td>140</td>
<td>618</td>
<td>65</td>
<td>182</td>
<td>39,97%</td>
<td>143</td>
<td>48</td>
<td>809</td>
<td>10.1%</td>
</tr>
<tr>
<td>IPEC</td>
<td>180</td>
<td>90</td>
<td>270</td>
<td>23</td>
<td>21</td>
<td>16,30%</td>
<td>22</td>
<td>63</td>
<td>355</td>
<td>4.4%</td>
</tr>
<tr>
<td>PRESIDÊNCIA</td>
<td>109</td>
<td>60</td>
<td>169</td>
<td>17</td>
<td>8</td>
<td>14,79%</td>
<td>4</td>
<td>31</td>
<td>204</td>
<td>2.5%</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>3383</td>
<td>2238</td>
<td>5621</td>
<td>466</td>
<td>519</td>
<td>798**</td>
<td>1584</td>
<td>8003</td>
<td><strong>100%</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>
BUDGET  (gross figures in US$ equivalent)

Governmental:  183,000,000.00

Direct sales:  90,000,000.00

Total:  273,000,000.00
RESEARCH & TECHNOLOGY

BIOMEDICAL
• emphasis in genomics and proteomics, geographic tropical pathology, strategic research – PDTIS & PDTSP

PUBLIC HEALTH
• epidemiological and environmental health, health services, health policy and planning, social sciences applied to health

CLINICAL
• clinical patterns, pathological manifestations, differential diagnosis, therapeutic evaluation
MAIN PRIORITY DISEASES

Chagas disease, Bubonic plague
Malaria, Leprosy
Schistosomiasis, Tuberculosis
Leishmaniasis, Meningitis
Filariasis, Hepatitis
Leptospirosis, Helminthoses
Yellow Fever, Mycosis
Dengue, Measles
Cholera, Rubella
HIV-AIDS
RESEARCH MANAGEMENT

Research Projects: 950 in 2002

Indexed Publications: 722
Conferences: 641
Book Chapters: 90
Scientific Events: 80
Books: 29

Technology transfer: 10 years

Concealed agreement: 26
Technology transfer contracts: 9
Patent licensing contracts: 29
Transfer of biological material: 3
Technological cooperation agreements: 76
## PATENTS (1989-2004)

<table>
<thead>
<tr>
<th>SECTOR</th>
<th>REQUESTED</th>
<th></th>
<th>CONCEDED</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BRAZIL</td>
<td>ABROAD</td>
<td>TOTAL</td>
<td>BRAZIL</td>
<td>ABROAD</td>
</tr>
<tr>
<td>PHARMACEUTICALS</td>
<td>15</td>
<td>12</td>
<td>27</td>
<td>02</td>
<td>12</td>
</tr>
<tr>
<td>VACCINES &amp; ANTIGENS</td>
<td>05</td>
<td>28</td>
<td>33</td>
<td>01</td>
<td>19</td>
</tr>
<tr>
<td>DIAGNOSTIC KITS</td>
<td>07</td>
<td>06</td>
<td>13</td>
<td>02</td>
<td>03</td>
</tr>
<tr>
<td>EQUIPMENT</td>
<td>07</td>
<td>-</td>
<td>07</td>
<td>03</td>
<td>-</td>
</tr>
<tr>
<td>BIOINSECTICIDES</td>
<td>02</td>
<td>08</td>
<td>10</td>
<td>01</td>
<td>03</td>
</tr>
<tr>
<td>METHOD FOR IDENTIFICATION OF UNICELULAR ORGANISMS</td>
<td>03</td>
<td>01</td>
<td>04</td>
<td>01</td>
<td>01</td>
</tr>
<tr>
<td>OTHERS</td>
<td>02</td>
<td>02</td>
<td>04</td>
<td>04</td>
<td>01</td>
</tr>
<tr>
<td>TOTAL</td>
<td>41</td>
<td>57</td>
<td>98</td>
<td>14</td>
<td>39</td>
</tr>
</tbody>
</table>
# STRATEGIC PROJECTS

**PDTIS – Health Product Technological Development Program**

- Recombinant and DNA Vaccines - 15
- Applied Genomics and Proteomics - 15
- Drugs and Bioinsecticides - 20
- Diagnostic Materials - 19
  
  **Total:** 69

**PDTSP – Public Health Technology Development Program**

- Clinical Services - 5
- Health Surveillance - 11
- Public Health - 8
  
  **Total:** 24
# VACCINE PRODUCTION

*(in thousands)*

<table>
<thead>
<tr>
<th>YEAR TYPES</th>
<th>1998</th>
<th>1999</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yellow fever</td>
<td>53,440</td>
<td>65,000</td>
<td>38,438</td>
<td>14,975</td>
<td>33,072</td>
<td>29,072</td>
</tr>
<tr>
<td>Measles</td>
<td>5,053</td>
<td>5,900</td>
<td>7,500</td>
<td>10,000</td>
<td>4,595</td>
<td></td>
</tr>
<tr>
<td>Polio</td>
<td>47,339</td>
<td>41,131</td>
<td>18,968</td>
<td>58,290</td>
<td>71,708</td>
<td>30,708</td>
</tr>
<tr>
<td>Hib</td>
<td>14,577</td>
<td>15,901</td>
<td>2,566</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningitis C</td>
<td></td>
<td>500</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPT + Hib</td>
<td>24,953</td>
<td>8,007</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>105,832</td>
<td>112,031</td>
<td>79,483</td>
<td>99,666</td>
<td>136,894</td>
<td>67,787</td>
</tr>
</tbody>
</table>
VACCINES & DIAGNOSTIC KITS

New Developments

- Double Viral (Measles & Rubella)
- Triple Viral (Measles, Mumps & Rubella)
- Meningitis B + C
- Tetra Bacterial (DTP + Haemophilus influenza)
- Quick Tests and Molecular Tests for: HIV
  Dengue
  Leptospirosis
  Leishmaniasis
PHARMACEUTICAL PRODUCTION

Capacity: 3 billion units of pharmaceuticals per year

WITH THE NEW PRODUCTION PLANT, IT WILL BE POSSIBLE TO TRIPLE THIS CAPACITY

Production includes:

- Phyto-therapeutic drugs / Bio-insecticides
- Therapeutics for malaria, leishmaniosis, leprosy, tuberculosis, Chagas disease, hepatitis B/C and HIV-AIDS
- Drugs for allergy, hypertension, diabetes and anemia

Zidovudine, Nevirapine, Lamivudine, Indinavir, Estavudine, Didanosine
EDUCATION & TRAINING

GRADUATE DEGREE PROGRAMS
(Master’s and Doctorate)

Cellular and Molecular Biology
Parasitology
Tropical Medicine
Public Health
Maternal and Child Health
Pathology
History of Health Science

Health & Society
Health Policy & Planning
Epidemiology
Endemic Diseases
Health, Work & Environment
Toxicology
EDUCATION & TRAINING

GRADUATE NON-DEGREE PROGRAMS

- Specialization
- Updating & Refreshment
- Distance Education
- Vocational Programs
- Technical School

- Biodiagnostics in health
- Sanitary surveillance
- Environmental health
- Health service management
- Equipment maintenance
<table>
<thead>
<tr>
<th>Category</th>
<th>no. courses</th>
<th>students</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degree Programs</td>
<td>20</td>
<td>400</td>
</tr>
<tr>
<td>MPH</td>
<td>10</td>
<td>300</td>
</tr>
<tr>
<td>PhD</td>
<td>10</td>
<td>100</td>
</tr>
<tr>
<td>Non-degree Programs</td>
<td>99</td>
<td>2064</td>
</tr>
<tr>
<td>Specialization</td>
<td>27</td>
<td>789</td>
</tr>
<tr>
<td>Up-grade</td>
<td>6</td>
<td>165</td>
</tr>
<tr>
<td>Refreshment</td>
<td>51</td>
<td>1042</td>
</tr>
<tr>
<td>Residency</td>
<td>15</td>
<td>68</td>
</tr>
<tr>
<td>Professional education</td>
<td>30</td>
<td>654</td>
</tr>
<tr>
<td>Technical level</td>
<td>7</td>
<td>164</td>
</tr>
<tr>
<td>Intermediate level</td>
<td>23</td>
<td>490</td>
</tr>
<tr>
<td>Distance education</td>
<td>9</td>
<td>13370</td>
</tr>
<tr>
<td>Specialization</td>
<td>2</td>
<td>9650</td>
</tr>
<tr>
<td>Refreshment</td>
<td>6</td>
<td>3220</td>
</tr>
<tr>
<td>Up-grade</td>
<td>1</td>
<td>500</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>158</strong></td>
<td><strong>16488</strong></td>
</tr>
</tbody>
</table>
Health & Medical Care - Reference Centers

IPEC - INFECTIOUS DISEASES

Leishmaniasis, Mycoses, Tuberculosis and other mycobacteria
Sexually transmitted diseases and HIV-AIDS
Dengue and other acute fevers

IFF - MATERNAL & INFANT CARE

High risk pregnancy, Neonatology, Genetic counseling,
Lactation and the human milk bank, Pediatrics and
Cervical and uterine cancers

ENSP / HEALTH CENTER - PRIMARY CARE

Health promotion protocols (senior citizens, Aids, drug addiction )
Pre-natal care
Immunization program
Quality Control in Health Reference Laboratory

**National Network of Epidemiology Surveillance Laboratories**

Coordination + participation in 23 FIOCRUZ labs
(including research, services and training)

**National Network of Oficial Laboratories in Health Quality Control**

Coordination and cooperation with ANVISA
Development of methodology and processes
Definition of Guidelines, Rules and Legislation
Control of products for human consumption
Sample analysis and reports
Courses and Seminars
Health Communication and Information

PERIODICALS

Memórias do Instituto Oswaldo Cruz (93 years)
Cadernos de Saúde Pública (17 years)
História, Ciências & Saúde Magazine (8 years)
RADIS program – Diffusion of Health Information (20 years)

CICT & LIBRARIES

196,000 books, 8,500 journals and 5,000 theses
Virtual Library Network in Health – PAHO/BIRME

LIFE MUSEUM

Exhibits, courses and seminars

HEALTH CHANNEL

Broadcast over Internet, cable and open channels
International Cooperation

Demand / Receipt

Canada: Health Promotion in Action
France: INSERM – IRD – PASTEUR – AMSUD/PASTEUR
USA: Fogarty/NIH – NIAID/NIH

Interchange

IBSA: Trilateral Agreement (ICMR-MRC-FIOCRUZ)

Offer / Delivery

WHO Collaborative Centers (education, research, services)
PAHO/TCC: Latin American Countries
DNDi: Drugs for Neglected Diseases
JICA / CPLP / PALOPS: Education and Training in Public Health
ABC: Feasibility Study for Anti-retroviral Production
THANK YOU